HVR Solar Advances India's Solar Tech Leadership with 2GW N-Type Topcon Manufacturing Hub
Delhi, India, 26th June 2025: HVR Solar Pvt Ltd is betting big on next-generation solar technology with the launch of a 2GW annual production facility dedicated to N-Type Topcon bifacial modules in Sonepat, Haryana. The facility, operational from Q3 2025, represents a strategic pivot toward high-efficiency solar solutions as the industry grapples with evolving performance demands and technological convergence.
The 6.5-acre facility will produce modules with maximum capacity of 715Wp, positioning HVR Solar in the premium segment where efficiency gains translate directly to improved project economics. The move comes as global solar manufacturers race to commercialize advanced cell technologies, with N-Type Topcon emerging as a leading candidate to replace traditional PERC technology.
"We're witnessing a fundamental shift in solar technology adoption, where efficiency improvements of even 2-3% can determine project viability," said Mr. Rishabh Aggarwal, Director, HVR Solar Pvt Ltd. "Our investment in N-Type Topcon technology positions us at the forefront of this transition, offering developers a compelling value proposition in an increasingly competitive market."
The technology choice reflects careful market analysis of emerging trends in solar photovoltaics. N-Type Topcon cells offer superior efficiency compared to conventional P-Type PERC cells, with lower temperature coefficients and reduced light-induced degradation. These characteristics become particularly valuable in utility-scale installations where marginal efficiency gains compound over project lifecycles.
Bifacial module design adds another dimension to performance optimization, enabling energy generation from both sides of the panel. This capability can increase energy yield by 10-30% depending on installation conditions, making it particularly attractive for ground-mounted utility projects and agrivoltaics applications.
Mr. Sagar Sachdev, Executive Director, HVR Solar Pvt Ltd, highlighted the strategic rationale: "The convergence of N-Type cell technology with bifacial design represents the current sweet spot in solar module development. We're not just manufacturing products; we're delivering solutions that address real-world challenges faced by project developers in optimizing land use and maximizing energy density."
The Sonepat location was selected after comprehensive analysis of logistics, infrastructure, and talent availability. Haryana's industrial ecosystem provides access to skilled manufacturing workforce while ensuring proximity to key markets in northern India. The state's supportive industrial policies and robust infrastructure development further enhance the facility's long-term viability.
HVR Solar's expansion occurs against the backdrop of India's evolving solar manufacturing landscape. The implementation of ALMM regulations and PLI incentives has catalyzed domestic manufacturing growth, while rising global trade tensions have created opportunities for Indian manufacturers to capture market share previously dominated by Chinese suppliers.
The company's technology roadmap extends beyond current N-Type Topcon offerings, with research and development initiatives exploring heterojunction technology & Solar Cells Manufacturing in near future. This forward-looking approach positions HVR Solar to adapt to evolving technology paradigms in the rapidly advancing photovoltaics sector.
Manufacturing operations will incorporate Industry 4.0 principles, including automated quality control systems, predictive maintenance protocols, and real-time production optimization. These capabilities are essential for maintaining consistent product quality while achieving competitive manufacturing costs in the global market.
The facility's design emphasizes flexibility and scalability, enabling rapid adaptation to changing market demands and technology evolution. Modular production lines can be reconfigured to accommodate different cell sizes and module configurations, ensuring long-term asset utilization despite technological uncertainties.
Market dynamics favor high-efficiency module adoption, with utility-scale developers increasingly prioritizing energy density over initial cost considerations. This trend, combined with declining balance-of-system costs, creates favorable conditions for premium module technologies like N-Type Topcon bifacial designs.
HVR Solar's strategic positioning targets the intersection of technological advancement and market opportunity, leveraging India's manufacturing cost advantages while delivering performance capabilities that meet global standards. The initiative represents a calculated bet on technology leadership as a sustainable competitive advantage in the commoditizing solar module market.
For more information please visit: https://hvrsolar.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
41 minutes ago
- Business Standard
Ketan Kumar Joshi named J&K Bank CFO for 3-year term, replaces Fayaz Ganai
The Bank notified the appointment to the stock exchanges in accordance with Sebi Regulations Press Trust of India Srinagar The Jammu and Kashmir Bank on Sunday announced the appointment of Ketan Kumar Joshi as its new chief financial officer for a term of three years. Joshi has replaced Fayaz Ahmad Ganai, a spokesperson of the J&K Bank said. The Bank notified the appointment to the stock exchanges in accordance with Sebi Regulations. "A seasoned professional in banking and finance, Joshi brings over two decades of extensive experience across Indian and international financial institutions," the spokesperson said. Before joining the J&K Bank, Joshi served as CFO at North East Small Finance Bank Ltd. (2019-2024), where he successfully led a number of critical initiatives. He also spearheaded the bank's system migration from FIS (PROFILE) to BSG (TURING), ensuring capital growth aligned with business expansion and regulatory requirements. Joshi has served in Afghanistan with Maiwand Bank, Bakhtar Bank, and Ghazanfar Bank. He also served as senior vice president at Bank of Tokyo-Mitsubishi UFJ Ltd, Mumbai. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Time of India
43 minutes ago
- Time of India
Contribute to stable borders: Chinese President Xi urges residents of Tibetan village bordering Arunachal Pradesh
Beijing: Chinese President Xi Jinping on Sunday called on the Tibetan residents of a village situated near the Indian border to contribute towards fostering prosperity and stability in the border areas. "Learning that the village has undergone new changes in recent years and villagers' incomes have increased, I feel happy for you," Xi replied to a letter received from residents of Nyingchi, a prefecture-level area located close to the Arunachal Pradesh border. China claims Arunachal Pradesh as part of South Tibet, which is firmly rejected by India. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Memperdagangkan CFD Emas dengan salah satu spread terendah? IC Markets Mendaftar Undo Xi visited Nyingchi in 2021, becoming the only Chinese president to have visited the border areas of Tibet. Xi, in his letter, voiced hope that Nyingchi residents will, under the guidance of the Communist Party's policies to develop border areas and improve people's lives, do an even better job in protecting the natural beauty of the plateau region, developing the village's tourist brand, and contributing to building a prosperous and stable border area. Live Events In recent years, China has built a number of villages along the Tibetan border areas to ensure border security and development. In his letter, Xi also urged the people in the Tibet Autonomous Region to uphold ethnic solidarity and create a happier and better life, the state-run Xinhua news agency reported. During his 2021 visit to Nyingchi, Xi visited the Nyang River Bridge to inspect the ecological preservation in the basin of the Brahmaputra River , which is called Yarlung Zangbo in the Tibetan language. Last year, China approved the construction of the world's largest dam, stated to be the planet's biggest infrastructure project, costing USD 137 billion, on the Brahmaputra river in Tibet, which has raised concerns in the riparian states of India and Bangladesh.
Mint
an hour ago
- Mint
Torrent Pharma to acquire controlling stake in JB Chemicals from KKR
Ahmedabad-based drugmaker Torrent Pharmaceuticals is set to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JB Pharma) from global investment firm KKR, at an equity valuation of ₹25,689 crore. The deal will be followed by a merger of the two entities, the company announced on Sunday evening. The deal will strengthen Torrent's presence in the Indian market, as well as facilitate its entry into the fast-growing contract development and manufacturing (CDMO) segment. Torrent will acquire a 46.39% equity stake (on a fully diluted basis) in JB Pharma through a share purchase agreement for ₹11,917 crore at ₹1,600 per share, followed by a mandatory open offer to acquire up to 26% of the company's shares from public shareholders, at an open offer price of ₹1,639.18 per share. Torrent also intends to acquire up to 2.80% of equity shares from certain employees of JB Pharma at the same share price as KKR, the company said in a release. The investment in JB Pharma yielded an over 5x return for KKR with a gross internal rate of return of about 36%, a person aware of the development, who did not wish to be quoted, told Mint. KKR has had a strong track record of healthcare investments in India, including a $600 million financing to Manipal Group recently and a 5x return on its investment in Max Healthcare in 2022. The acquisition will be followed by a merger between Torrent and JB Pharma through a scheme of arrangement. JB Pharma's shares rose 2.3% to ₹1,792.20 apiece, while those of Torrent Pharma settled 4.7% higher at ₹3,375 on the NSE on Friday. The acquisition will provide Torrent access to a fast-growing India franchise, with JB's leading brands in the chronic segment, and entry into untapped therapeutic areas like ophthalmology, strengthen Torrent's market share in the Indian market, and facilitate its entry into the CDMO segment. It will also aid consolidation in key international markets, the company said. 'Torrent's deep India presence and JB Pharma's fast growing India business, combined with the CDMO and international footprint, offers immense potential to scale both revenue and profitability," Samir Mehta, executive chairman, Torrent Pharmaceuticals, said in the statement. 'Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent," he added. Torrent Pharma was engaged in prolonged talks to acquire KKR's stake in JB Pharma last year. The deal, however, fell through over valuation concerns. KKR acquired a 54% stake in JB Pharma from the promoters, the Mody family, in July 2020 for about ₹3,100 crore, or ₹745 per share. The investment firm sold over 5% of stake in the company in March 2025 through block deals for ₹1,459 crore, bringing its holding down to 47.84%. Torrent Pharmaceuticals has grown over the years through inorganic moves. In 2017, it acquired women's healthcare brands from Novartis, as well as Unichem's Indian branded business along with its Sikkim plant. In 2022, it acquired Curatio Healthcare for ₹2,000 crore. In an interview with the Economic Times earlier this month, Torrent's managing director-designate Aman Mehta said the company is aiming to be one of the top three pharma companies in the Indian market in the next three to five years. JB Pharma is one of the fastest growing pharma companies in India, and comes with flagship brands such as Cilacar, Metrogyl, Nicardia and Rantac. The company also exports its finished formulations to over 40 countries, including the US, and is a leading CDMO player in the segment of medicated lozenges. JB Pharma recorded revenue of ₹3,918 crore in FY24-25, growing 12% year-on-year. Of this, its revenue from the domestic market was ₹2,269 crore, growing 20% YoY. 'Over the past five years, JB Pharma has emerged as one of India's fastest growing pharmaceutical players, owing to KKR's strategic guidance, stewardship of our independent directors and a focused strategic and executional excellence by the management team. We have built a strong foundation to deliver market-leading growth as well as consistent improvement in profitability in the medium and long term," said Nikhil Chopra, chief executive officer and whole time director of JB Pharma.
